Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475033 | 1.00 | ATM (0.62) | ATMCTSKELANECTRB1CTSS | |
| SCHEMBL16829101 | 0.88 | ATM (0.53) | ATMCTSKELANECTRB1CTSS | |
| SCHEMBL21048451 | 0.88 | ATM (0.53) | ATMCTSKELANECTRB1CTSS | |
| SCHEMBL21265212 | 0.83 | KMT2A (0.46) | ATM | |
| SCHEMBL22370927 | 0.81 | ATM (0.67) | ATMCTSKELANECTRB1CTSS | |
| SCHEMBL22370926 | 0.81 | ATM (0.67) | ATMCTSKELANECTRB1CTSS | |
| SCHEMBL7414757 | 0.80 | ATM (0.58) | ATMCTSKELANECTRB1CTSS | |
| SCHEMBL12971777 | 0.80 | ATM (0.55) | ATMCTSKCTSSCTSLCTSB | |
| SCHEMBL1505365 | 0.80 | ATM (0.55) | ATMCTSKCTSSCTSLCTSB | |
| SCHEMBL19867876 | 0.79 | ATM (0.51) | ATMCTSKELANECTRB1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544145-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190248789-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEVELOPMENT 1, INC. | 2019-08-15 | — | — | US | disclosed |
| EP-2215049-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10316039-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2019-06-11 | — | — | US | disclosed |
| US-20160318927-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160296501-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2015095128-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-0628035-A4 | RETROVIRAL PROTEASE INHIBITORS. | SMITHKLINE BEECHAM CORP (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0628035-A1 | RETROVIRAL PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993017003-A1 | RETROVIRAL PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318927-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX2, P2RX1 | ATM 4023/4885CTSK 4633/4885ELANE 2939/4885 |
| US-10544145-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX2, P2RX1 | ATM 4023/4885CTSK 4633/4885ELANE 2939/4885 |
| US-20160296501-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX2, P2RX1 | ATM 3730/4885CTSK 4711/4885ELANE 1786/4885 |
| US-20190248789-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX2, P2RX1 | ATM 4023/4885CTSK 4633/4885ELANE 2939/4885 |
| US-10316039-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX2, P2RX1 | ATM 4023/4885CTSK 4633/4885ELANE 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.